Andrew J Wood

Venture Partner

Andrew joined Advent in 2011 after 18 years of experience in the pharmaceutical industry with Eli Lilly & Co. At Lilly, he was initially responsible for clinical development and registration of new molecules, principally in relation to neurological and psychiatric disorders. He then managed both clinical and preclinical discovery organisations, across multiple therapeutic areas, in Europe and in Asia. Latterly, Andrew was leader of Eli Lilly’s in-licensing and business development organisation in Europe. Within this role, he had responsibility for evaluating drug and technology development projects and for structuring collaborations with external partners in the biotechnology sector and in academia.

Andrew retired from Eli Lilly in February 2010, since when he has worked as an independent consultant to the pharmaceutical and biotech sectors.

Andrew graduated in Natural Sciences from Cambridge University and in Clinical Medicine from the Oxford University Medical School, and spent 10 years in academic medicine before entering the pharmaceutical industry.

Andrew has advised several Advent portfolio companies including NeRRe Therapeutics, and is currently a Director of Calcico.

Assistant: Amber Rosamond
E: This email address is being protected from spambots. You need JavaScript enabled to view it.
T: +44 (0)20 7932 2157